ValuEngine Upgrades Pro-Dex (PDEX) to “Buy”
ValuEngine upgraded shares of Pro-Dex (NASDAQ:PDEX) from a hold rating to a buy rating in a research report report published on Thursday morning.
Shares of PDEX opened at $10.30 on Thursday. The firm has a market capitalization of $43.10 million, a P/E ratio of 19.04 and a beta of -0.20. Pro-Dex has a twelve month low of $6.05 and a twelve month high of $11.00.
Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, August 30th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.16. Pro-Dex had a return on equity of 13.54% and a net margin of 9.94%.
Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and machined parts.
Featured Story: How to Profit and Limit Losses With Stop Orders
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.